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Supplementary Results
Supplementary Table S1. Effect of Atglistatin on metabolic plasma parameters and tissue TG levels. C57Bl6 mice were fasted over night and received Atglistatin by oral gavage or intraperitoneal injection (200 µmol/kg). After 8 h, blood was taken retro-orbitally and mice were sacrificed. Plasma TG, glucose, total cholesterol (TC), beta-hydroxybutyrate (beta-HB), and plasma insulin levels were measured using commercial assays. Data are presented as mean ± S.D. (n = 4-7; *, p < 0.05 **, p < 0.01).
Oral
Control + Atglistatin
Triglycerides (mmol/L) 0.58 ± 0.08 0.33 ± 0.14** Glucose (mg/dL) 78. 85 ± 7.99 86.85 ± 12.19 TC (mmol/L) 3.25 ± 0.44 3.12 ± 0.25
Insulin (ng/ml) 0.17 ± 0.06 0.18 ± 0.07
Intraperitoneal
Control + Atglistatin
Triglycerides ( h after transfection, cells were harvested using a cell scraper and lysed in buffer C (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % NP40) on ice. After centrifugation (1000 g, 4°C, 10 min), the supernatant (0.5 mg protein) was incubated with 10 µl Anti-Flag-Agarose over night at 4°C. After extensive washing in buffer C, the Flag-Agarose was heated to 99°C for 10 min in 2 x SDS sample buffer.
Thereafter, the input and the immunoprecipitated fraction were adjusted to SDS-PAGE. Flag-and Histagged proteins were detected using Flag-and His-antibodies.
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Supplementary Note High pressure hydrogenation experiments were performed using the H-CubeTM continuous hydrogenation unit (HC-2.SS) from Thales Nanotechnology Inc. running with a Knauer
Smartline pump 100 and equipped with a 10 mL ceramic pump head. As hydrogenation catalyst 10 % Pd/C catalyst cartridges were used (Thales Nanotechnology Inc., THS01111, 10% Pd/C CatCartTM A 10 mL one-neck round-bottom flask was charged with 250.0 mg (0.24 mL, 1.825 mmol, 1.04 eq) 4-ethoxyaniline which was dissolved in 3.1 mL acetic acid at 10 °C (ice bath). To this cooled solution 128.0 mg (1.861 mmol, 1.06 eq) NaNO 2 in 0.5 mL conc. H 2 SO 4 were added and the reaction mixture was stirred at 10 °C for 1 h. In a second 25 ml one-neck round-bottom flask 288.6 mg (0.24 mL, 1.755 mmol, 1.0 eq) ethyl-4-chloro-3-oxobutanoate were dissolved in a mixture of 1.3 mL acetic acid and 2.6 mL water and cooled to 0 °C (ice bath + NaCl). After one hour stirring at 10 °C the generated solution of the diazonium salt was given to the second solution at 0 °C and stirred for further 15 min at this temperature. An aqueous solution of 1.58 g (19.305 mmol, 11 eq) NaOAc in 3.0 mL water was added to the reaction mixture at 0 °C and the product precipitated. Stirring at rt over night, filtration, washing with a small amount of water and drying under high pressure yielded the crude product which was used in the next reaction step without further purification. (Cl-CH 2 ), 46.9 (CH 2 ), 14.5 (CH 3 ), 13.9 (CH 3 ).
Ethyl 1-(4-ethoxyphenyl)-4-hydroxy-1H-pyrazole-3-carboxylate (1)
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Ethyl 1-(4-ethoxyphenyl)-1H-pyrazole-3-carboxylate (2)
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Ethyl 1H-pyrazole-3-carboxylate (7)
A 100 mL Schlenk tube was dried under vacuum, filled with nitrogen and charged with 0.5 g 0.05 eq) PdCl 2 (dppf)*DCM, 2.39 g (15.8 mmol, 2.1 eq) CsF and 60 mL anhydrous DME. The suspension was degassed by vacuum/N 2 cycles, heated to 80°C and stirred for 14 h. After full conversion according to TLC and GC-MS (filtration through a pipette filled with celite) the reaction mixture was cooled to room temperature and filtered through a pad of celite, which was rinsed with EtOAc. The solvent of the remaining filtrate was removed under reduced pressure.
The resulting dark brown solid was then purified via flash chromatography (CH/EtOAc = 19/1, size: 8.0 x 6.5 cm, 131 g silica gel) and dried under vacuum. 
